Back to School: How biopharma can reboot drug development. Access exclusive analysis here

SUPG's Orathecin misses Phase III endpoint

SuperGen (SUPG) said its Orathecin rubitecan chemotherapeutic missed the primary endpoint of improved median survival in a Phase III

Read the full 194 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE